The case for & against
Bull & Bear analysis
The CombiMatrix Corporation (formerly traded as CBMX) was a prominent player in the field of molecular diagnostics, specifically focused on providing advanced genetic testing and diagnostic services. The company's expertise revolved around offering cutting-edge solutions in reproductive health, pediatric health, and cancer testing, integrating genetic insights into healthcare decision-making. However, it ceased to operate as an independent entity after the acquisition by Invitae Corporation (NYSE: NVTA) in November 2017. Post-acquisition, CombiMatrix's operations are integrated within Invitae, which is a leader in genetic information and diagnostics, emphasizing the ongoing importance of genetic insights in modern medicine.
Bull says
- ↑$33 M acquisition added CombiMatrix’s reproductive and cancer tests to Invitae’s lineup.
- ↑Precision medicine tailwinds drive ~20–25% annual growth in genetic testing.
- ↑Invitae’s R&D investment accelerates integration of CombiMatrix technologies.
- ↑Expanded test catalog and scale enhance Invitae’s competitive moat.
- ↑Synergies aim to cut per-test costs and improve gross margins.
Bear says
- ↓Culture and IT integration of CombiMatrix may face delays.
- ↓Competitors like Illumina and Myriad heighten molecular diagnostics rivalry.
- ↓Market saturation risks eroding pricing power and test profitability.
- ↓Acquisition premium risks if Invitae fails to hit growth targets.
- ↓Heavy cash burn and funding needs could strain Invitae’s balance sheet.
- ↓Reimbursement uncertainties may limit uptake of new genetic tests.